
My Opinion | 122657 Views | Aug 14,2021
Feb 1 , 2025
By Jayasree K. Iyer
Natural disasters intensify risks for those in conflict zones, where shortages of essential vaccines and treatments leave communities susceptible to common infections. Case reports from field clinics suggest that even small disruptions in the supply of generic medications can result in outbreaks of preventable illnesses. Despite these risks, no universal framework is compelling companies to build redundancy into shipping networks or develop products suited for hot climates where cold-chain storage may be inaccessible, writes Jayasree K. Iyer, CEO of the Access to Medicine Foundation, in this momentary provided by project Syndicate (PS).
Every year, 21.5 million people are forcibly displaced by floods, droughts, wildfires, and storms. This number is set to rise dramatically over the coming decades, with up to 1.2 billion people expected to be driven from their homes by 2050. The unfolding climate crisis is not only a humanitarian disaster but also a global health emergency.
Climate displacement poses both direct and indirect threats to public health. Disrupting care services deprives affected communities of access to doctors, hospitals, and pharmacies. Climate-induced migration also exacerbates poverty, overcrowding, and social instability. Food production is often severely affected, while unsanitary living conditions fuel the spread of infectious diseases.
As the climate crisis threatens to derail global efforts to achieve the United Nations Sustainable Development Goals (SDGs), the health and well-being of hundreds of millions of people in the developing world are at risk. High-income countries are not immune: In the United States alone, 3.1 million adults were displaced or evacuated due to natural disasters in 2022.
Pharmaceutical companies should play a pivotal role in bolstering global health resilience. Their involvement is particularly critical in conflict zones at the forefront of the climate-displacement crisis, where life-saving medicines and vaccines are often in short supply. While the pharmaceutical industry has made strides in reducing carbon dioxide emissions and adopting more sustainable practices, its efforts fall far short of mitigating climate-related disruptions to supply chains. These vulnerabilities were on full display in 2017, when Hurricane Maria devastated Puerto Rico's drug manufacturing sector, which at the time accounted for nearly 10pc of all drugs consumed in the US.
Some pharmaceutical companies, such as Novartis and Novo Nordisk, have launched targeted programs to aid populations displaced by extreme weather events, while others have donated cash or supplies in response to natural disasters. The demand for these donations has risen with increasing climate and humanitarian needs. Hikma, a generic medicine manufacturer founded in Jordan, reported four million dollars in donations in 2020, and 4.9 million dollars in 2023, mostly serving the needs in the surrounding region.
No company has developed a comprehensive strategy to ensure displaced communities have sustained access to health products. A more holistic approach is needed. Amid the ongoing climate-displacement crisis, pharmaceutical companies should adopt a four-pronged strategy to strengthen healthcare systems.
For starters, they could help deliver medicines to vulnerable communities in remote areas by revamping their supply chains, from building redundancy into shipping networks to redesigning products to be more stable in hot climates where refrigeration may be unavailable. They should include robust systems for the large-scale distribution of generic drugs, frequently the most effective tools for managing disease outbreaks.
Pharmaceutical companies should invest in research and development to create vaccines, diagnostics, and therapeutics targeting climate-sensitive diseases. Rising global temperatures are accelerating the spread of mosquito-borne illnesses such as dengue, malaria, and Zika, as well as waterborne diseases like cholera and shigella, putting displaced populations at even greater risk.
Yet, despite the need for innovation, the 2024 Access to Medicine Index – which ranks the efforts of pharmaceutical companies to improve access to essential drugs in developing countries – shows that the Research and development (R&D) pipeline for emerging pathogens and neglected tropical diseases is drying up. Compounding this problem is the lack of research into new antibiotics to combat the escalating threat of antimicrobial resistance, exacerbated by extreme weather and poor sanitation.
Pharmaceutical companies should forge long-term partnerships with humanitarian organisations focused on climate displacement. Public-private collaborations have also proven effective in strengthening health resilience. Since 2010, for example, leading vaccine manufacturers like GSX and Pfizer have supplied Gavi, the Vaccine Alliance, with billions of vaccine doses, protecting vulnerable populations in some of the world's most resource-constrained countries.
Lastly, pharmaceutical companies should boost efforts to cut greenhouse-gas emissions across their value chains. While the climate impact of pharmaceuticals may get less attention than traditional manufacturing industries, the sector emits more CO2 per one million dollars of revenue than the automotive industry.
The active support and engagement of shareholders, employees, and other stakeholders is crucial. Investors, in particular, should encourage companies to align their business practices with global health and climate goals. This is not only an ethical choice but also one that promises long-term financial and reputational benefits. Climate displacement is not a distant or hypothetical threat; it is a rapidly escalating health emergency.
The pharmaceutical industry has a moral responsibility to act. To do so effectively, companies must get ahead of the curve and provide vital, life-saving treatments to those on the front lines of the climate crisis.
PUBLISHED ON
Feb 01,2025 [ VOL
25 , NO
1292]
My Opinion | 122657 Views | Aug 14,2021
My Opinion | 118771 Views | Aug 21,2021
My Opinion | 117222 Views | Sep 10,2021
My Opinion | 115032 Views | Aug 07,2021
Editorial | Feb 01,2025
Dec 22 , 2024 . By TIZITA SHEWAFERAW
Charged with transforming colossal state-owned enterprises into modern and competitiv...
Aug 18 , 2024 . By AKSAH ITALO
Although predictable Yonas Zerihun's job in the ride-hailing service is not immune to...
Jul 28 , 2024 . By TIZITA SHEWAFERAW
Unhabitual, perhaps too many, Samuel Gebreyohannes, 38, used to occasionally enjoy a couple of beers at breakfast. However, he recently swit...
Jul 13 , 2024 . By AKSAH ITALO
Investors who rely on tractors, trucks, and field vehicles for commuting, transporting commodities, and f...
Feb 1 , 2025
Urban renewal is seldom gentle to those on the receiving end of redevelopment. Take s...
Jan 25 , 2025
Grand ambitions have long driven Ethiopia's successive leaders, but they remain weigh...
Jan 18 , 2025
Adanech Abebie, the mayor of Addis Abeba, addressed last week a warm-up session for h...
A severe cash shortage squeezes the economy, and the deposit-to-loan ratio has slumpe...
Feb 1 , 2025
The incumbent Prosperity Party (PP) rallied 1,200 of its ranks amid a turbulent polit...
Feb 2 , 2025 . By AKSAH ITALO
A notable wave of lending rate increases is reshaping the financial sector, following...
Feb 2 , 2025 . By AKSAH ITALO
The coffee industry is reeling after the Ethiopian Coffee & Tea Authority (ECTA)...
Feb 2 , 2025 . By HAGOS GEBREAMLAK
The controversy surrounding the Addis Abeba Chamber of Commerce & Sectoral Associ...